Skip to main content
Altuviiio logo

ALTUVIIIO® Patient Experiences 


"My only regret is that I didn’t find out about [ALTUVIIIO] sooner.” 
 

Taking an active role in my treatment

I was not a partner in my own treatment, but more of a passenger. I believed that if a medication was approved for hemophilia, then it should be working. If it wasn’t, that meant I must be doing something differently than other people with hemophilia. I was constantly having bleeds when I was active, and I just knew I needed something that worked or else I would get worse and slip back into procrastinating on infusion days.
 

Making the switch

I felt slightly nervous about going to a new treatment. Even though others were having good results, I was worried it wouldn’t work for me. Once I decided to make the switch, my doctor got me in touch with the specialty pharmacy I used, worked with insurance, and answered all of my questions. I think I spoke with my HTC nurse 2 or 3 times after starting. My Sanofi Patient Representative called and checked in with me several times, making sure that I was receiving my factor, that there was no issues with it, and asking if I had any questions or concerns. I also utilized someone from the team to lock in the copay assistance. 
 

Expectation vs experience

ALTUVIIIO has done better than I expected. My levels are higher than I thought they would be, and I have not procrastinated a single time or pushed a dose back to the next day. To my surprise, I didn't have any breakthrough bleeds.

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Brad is a promotional speaker compensated by Sanofi. 

HTC=hemophilia treatment center.

Discover More Patient Experiences

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with Hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2025 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2508205-v1.0-11/2025 Last Updated: November 2025